Dimensional Fund Advisors LP Cuts Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Dimensional Fund Advisors LP decreased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 35.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,181 shares of the company's stock after selling 38,464 shares during the quarter. Dimensional Fund Advisors LP owned about 0.08% of Syndax Pharmaceuticals worth $1,441,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in shares of Syndax Pharmaceuticals by 54.3% in the second quarter. Assenagon Asset Management S.A. now owns 428,949 shares of the company's stock valued at $8,806,000 after acquiring an additional 151,021 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,335,353 shares of the company's stock worth $93,687,000 after acquiring an additional 718,051 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Syndax Pharmaceuticals by 18.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 291,826 shares of the company's stock worth $5,991,000 after buying an additional 46,463 shares during the last quarter. Kingdon Capital Management L.L.C. bought a new position in shares of Syndax Pharmaceuticals during the 4th quarter valued at $16,127,000. Finally, Nvwm LLC bought a new position in shares of Syndax Pharmaceuticals in the first quarter worth approximately $1,022,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Jefferies Financial Group initiated coverage on Syndax Pharmaceuticals in a report on Friday, June 28th. They set a "buy" rating and a $37.00 price target on the stock. HC Wainwright upped their target price on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, August 15th. Citigroup boosted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Bank of America raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a "buy" rating in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $35.89.

Syndax Pharmaceuticals Stock Up 5.1 %

Shares of SNDX stock traded up $0.93 during trading hours on Friday, hitting $19.13. 559,062 shares of the company's stock traded hands, compared to its average volume of 1,030,003. The stock's fifty day simple moving average is $19.33 and its two-hundred day simple moving average is $20.70. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -5.66 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a 12-month low of $11.22 and a 12-month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.11. The firm had revenue of $3.50 million during the quarter. During the same quarter last year, the firm earned ($0.64) earnings per share. The business's revenue was up 3499999990.0% on a year-over-year basis. On average, equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).